0R15 7941.0 -0.9233% 0R1E 7597.0 3.5437% 0M69 None None% 0R2V 182.6 3.0183% 0QYR 1369.0 -0.9407% 0QYP 409.9595 -0.4953% 0LCV 141.835 -0.3268% 0RUK None None% 0RYA 1604.0 -3.3153% 0RIH 170.0 -1.0477% 0RIH 169.0619 -0.5518% 0R1O 192.5 10152.996% 0R1O None None% 0QFP None None% 0M2Z 304.7 0.7273% 0VSO None None% 0R1I None None% 0QZI 472.0 0.6397% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-08T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -161.14200M | -122.44900M | -150.75100M | -193.63800M | -146.58400M |
| Minority interest | - | - | - | - | - |
| Net income | -161.82300M | -122.24500M | -149.91000M | -179.49600M | -146.65300M |
| Selling general administrative | 50.51M | 46.10M | 42.51M | 48.87M | 39.51M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3.65M | 40.96M | 20.08M | 15.98M | 14.41M |
| Reconciled depreciation | 10.11M | 9.84M | 9.98M | 9.20M | 5.58M |
| Ebit | -172.83400M | -127.01600M | -153.37700M | -208.31700M | -162.89100M |
| Ebitda | -162.72000M | -127.04600M | -153.96100M | -213.22900M | -157.31000M |
| Depreciation and amortization | 10.11M | -0.03000M | -0.58400M | -4.91200M | 5.58M |
| Non operating income net other | 1.58M | 4.57M | 2.64M | - | 12.92M |
| Operating income | -162.72000M | -127.01600M | -153.37700M | -208.31700M | -159.52300M |
| Other operating expenses | 166.37M | 167.98M | 173.45M | 224.30M | 173.94M |
| Interest expense | -1.57800M | 14.43M | -0.01600M | 0.00000M | 0.02M |
| Tax provision | 0.68M | -0.20400M | -0.84100M | 0.00000M | 0.07M |
| Interest income | 1.57M | - | - | 4.94M | 3.39M |
| Net interest income | 1.57M | - | -0.01600M | 0.03M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.68M | -0.20400M | -0.84100M | -14.14200M | 0.07M |
| Total revenue | 3.65M | 40.96M | 20.08M | 15.98M | 14.41M |
| Total operating expenses | 166.37M | 167.98M | 173.45M | 224.30M | 173.94M |
| Cost of revenue | - | - | - | 175.43M | 134.43M |
| Total other income expense net | 1.58M | 4.57M | 2.63M | 14.68M | 12.92M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -161.82300M | -122.24500M | -149.91000M | -193.63800M | -146.65300M |
| Net income applicable to common shares | -161.82300M | -122.24500M | -149.91000M | -193.63800M | -146.65300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 146.39M | 207.01M | 279.24M | 284.25M | 295.94M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.11M | 5.42M | 5.11M | 8.69M | 17.45M |
| Total liab | 191.48M | 174.51M | 196.46M | 220.52M | 222.59M |
| Total stockholder equity | -45.09100M | 32.50M | 82.78M | 63.73M | 73.35M |
| Deferred long term liab | - | - | - | - | 5.13M |
| Other current liab | 17.55M | 14.86M | 11.97M | 16.18M | 14.85M |
| Common stock | 802.83M | 749.85M | 694.09M | 539.55M | 375.15M |
| Capital stock | 802.83M | 749.85M | 694.09M | 539.55M | 375.15M |
| Retained earnings | -967.33700M | -805.51400M | -683.26900M | -533.35900M | -339.72100M |
| Other liab | 79.96M | 77.48M | 41.95M | 65.19M | 84.68M |
| Good will | - | - | - | - | - |
| Other assets | 3.72M | 3.80M | 3.77M | 44.30M | 53.74M |
| Cash | 88.50M | 150.56M | 184.50M | 147.16M | 174.82M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 71.52M | 64.20M | 121.04M | 118.15M | 130.04M |
| Current deferred revenue | 31.56M | 37.10M | 91.56M | 89.65M | 100.94M |
| Net debt | -50.88300M | -120.64800M | -155.19200M | -114.61400M | -164.41600M |
| Short term debt | 5.50M | 4.96M | 3.71M | 3.24M | 1.16M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 37.61M | 29.92M | 29.30M | 32.55M | 10.40M |
| Other stockholder equity | 119.44M | 87.98M | 71.57M | 57.28M | 37.77M |
| Property plant equipment | 17.28M | 22.27M | 29.20M | 54.47M | 39.93M |
| Total current assets | 98.54M | 162.56M | 230.04M | 185.48M | 202.27M |
| Long term investments | - | - | - | - | 50.00M |
| Net tangible assets | -37.21700M | 40.37M | 90.65M | 63.73M | 73.35M |
| Short term investments | - | - | - | - | - |
| Net receivables | - | 0.00000M | 30.00M | 20.00M | 10.00M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | 10.43M | 9.63M | - |
| Accounts payable | 16.91M | 7.28M | 13.79M | 9.07M | 13.09M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.02900M | 0.18M | 0.39M | 0.27M | 0.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 802.83M | 749.85M | 694.09M | 539.55M | 375.15M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -967.33700M | -805.51400M | -683.26900M | - | -339.72100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.72M | 3.80M | 3.77M | 44.30M | 53.74M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 47.85M | 44.44M | 49.20M | 98.77M | 93.67M |
| Capital lease obligations | 37.61M | 29.92M | 29.30M | 32.55M | 10.40M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.25500M | -0.56000M | -1.33800M | -3.91800M | -9.93800M |
| Change to liabilities | 12.23M | -4.15100M | -0.34400M | -19.48000M | 11.32M |
| Total cashflows from investing activities | -1.25500M | -0.56000M | -1.33800M | -3.91800M | -9.93800M |
| Net borrowings | - | - | - | - | -0.01600M |
| Total cash from financing activities | 67.19M | 55.83M | 154.54M | 164.40M | 65.09M |
| Change to operating activities | - | 2.04M | 4.61M | -13.82300M | -4.13400M |
| Net income | -161.82300M | -122.24500M | -149.91000M | -193.63800M | -146.65300M |
| Change in cash | -62.05800M | -33.93300M | 37.34M | -27.63600M | 32.33M |
| Begin period cash flow | 154.22M | 188.15M | 150.81M | 178.44M | 146.11M |
| End period cash flow | 92.16M | 154.22M | 188.15M | 150.81M | 178.44M |
| Total cash from operating activities | -127.78100M | -88.99300M | -115.98200M | -188.23100M | -22.86200M |
| Issuance of capital stock | 52.33M | 54.97M | 153.63M | 161.79M | 60.00M |
| Depreciation | 10.11M | 9.84M | 9.98M | 9.20M | 5.58M |
| Other cashflows from investing activities | 0.11M | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 2.04M | 4.61M | -5.45400M | -4.08200M |
| Change to account receivables | 0.00000M | 30.00M | 20.00M | 10.00M | -59.00000M |
| Sale purchase of stock | 66.08M | 55.83M | 94.66M | 164.40M | 65.11M |
| Other cashflows from financing activities | 14.86M | 0.86M | 0.91M | 2.61M | -60.00000M |
| Change to netincome | 17.21M | 16.41M | 14.30M | 19.51M | 15.64M |
| Capital expenditures | 1.36M | 0.56M | 1.34M | 3.92M | 9.94M |
| Change receivables | - | 30.00M | 20.00M | - | -59.00000M |
| Cash flows other operating | -1.96700M | -16.48700M | -8.13800M | - | 149.27M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -61.84800M | -33.72500M | 37.22M | - | 32.29M |
| Change in working capital | 6.72M | 7.01M | 9.65M | -23.30300M | 102.39M |
| Stock based compensation | 17.19M | 16.41M | 14.30M | 19.51M | 15.60M |
| Other non cash items | 0.01M | 25.13M | -32.03000M | 1.61M | 0.18M |
| Free cash flow | -129.14200M | -89.55300M | -117.32000M | -192.14900M | -32.80000M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd |
0.06 1.04% | 5.85 | - | - | 7.06 | 10.21 | 5.44 | -5.5782 |
| NVO Novo Nordisk A/S |
-0.6 0.47% | 126.69 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.75 2.21% | 127.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.58 2.09% | 418.82 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-0.54 0.58% | 91.82 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
Marina One East Tower, Singapore, Singapore, 018936
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul B. Bolno M.B.A., M.D., MBA | Pres, CEO & Director | 1974 |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer & Head of Platform Discovery Sciences | 1961 |
| Mr. Kyle B. Moran CFA | CFO & Principal Accounting Officer | 1971 |
| Kate Rausch | Head of Investor Relations | NA |
| Ms. Linda Rockett J.D. | Gen. Counsel | NA |
| Dr. Christopher Francis Ph.D. | Sr. VP of Corp. Devel. & Head of Emerging Areas | 1978 |
| Mr. Jonathan Rosin | Chief HR Officer | NA |
| Dr. Sridhar Vaddeboina Ph.D. | Sr. VP of Chemistry, Manufacturing & Controls | NA |
| Ms. Anne-Marie Li-Kwai-Cheung | Chief Devel. Officer | NA |
| Dr. Stephen L. Lake | Sr. VP & Head of Clinical Devel. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...